MAP3K19	NN
Is	VBZ
a	DT
Novel	JJ
Regulator	NNP
of	IN
TGF-b	NNP
Signaling	NN
That	WDT
Impacts	VBZ
Bleomycin-Induced	JJ
Lung	NN
Injury	NNP
and	CC
Pulmonary	NNP
Fibrosis	NNP
.	.

UNASSIGNED	NNP
:	:
Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
a	DT
progressive	JJ
,	,
debilitating	JJ
disease	NN
for	IN
which	WDT
two	CD
medications	NNS
,	,
pirfenidone	NN
and	CC
nintedanib	NN
,	,
have	VBP
only	RB
recently	RB
been	VBN
approved	VBN
for	IN
treatment	NN
.	.

The	DT
cytokine	NN
TGF-b	NN
has	VBZ
been	VBN
shown	VBN
to	TO
be	VB
a	DT
central	JJ
mediator	NN
in	IN
the	DT
disease	NN
process	NN
.	.

We	PRP
investigated	VBD
the	DT
role	NN
of	IN
a	DT
novel	JJ
kinase	NN
,	,
MAP3K19	NN
,	,
upregulated	VBN
in	IN
IPF	NN
tissue	NN
,	,
in	IN
TGF-b-induced	JJ
signal	NN
transduction	NN
and	CC
in	IN
bleomycin-induced	JJ
pulmonary	JJ
fibrosis	NN
.	.

MAP3K19	NN
has	VBZ
a	DT
very	RB
limited	JJ
tissue	NN
expression	NN
,	,
restricted	JJ
primarily	RB
to	TO
the	DT
lungs	NNS
and	CC
trachea	NN
.	.

In	IN
pulmonary	JJ
tissue	NN
,	,
expression	NN
was	VBD
predominantly	RB
localized	JJ
to	TO
alveolar	JJ
and	CC
interstitial	JJ
macrophages	NNS
,	,
bronchial	JJ
epithelial	JJ
cells	NNS
and	CC
type	NN
II	CD
pneumocytes	NNS
of	IN
the	DT
epithelium	NN
.	.

MAP3K19	NN
was	VBD
also	RB
found	VBN
to	TO
be	VB
overexpressed	VBN
in	IN
bronchoalveolar	JJ
lavage	NN
macrophages	NNS
from	IN
IPF	NN
patients	NNS
compared	VBN
to	TO
normal	JJ
patients	NNS
.	.

Treatment	NN
of	IN
A549	NN
or	CC
THP-1	NN
cells	NNS
with	IN
either	CC
MAP3K19	NN
siRNA	NN
or	CC
a	DT
highly	RB
potent	JJ
and	CC
specific	JJ
inhibitor	NN
reduced	VBD
phospho-Smad2	NN
		CD
3	CD
nuclear	JJ
translocation	NN
following	VBG
TGF-b	NN
stimulation	NN
.	.

TGF-b-induced	JJ
gene	NN
transcription	NN
was	VBD
also	RB
strongly	RB
inhibited	VBN
by	IN
both	CC
the	DT
MAP3K19	NN
inhibitor	NN
and	CC
nintedanib	NN
,	,
whereas	IN
pirfenidone	NN
had	VBD
a	DT
much	RB
less	RBR
pronounced	JJ
effect	NN
.	.

In	IN
combination	NN
,	,
the	DT
MAP3K19	NN
inhibitor	NN
appeared	VBD
to	TO
act	VB
synergistically	RB
with	IN
either	CC
pirfenidone	NN
or	CC
nintedanib	NN
,	,
at	IN
the	DT
level	NN
of	IN
target	NN
gene	NN
transcription	NN
or	CC
protein	NN
production	NN
.	.

Finally	RB
,	,
in	IN
an	DT
animal	NN
model	NN
of	IN
IPF	NN
,	,
inhibition	NN
of	IN
MAP3K19	NN
strongly	RB
attenuated	VBD
bleomycin-induced	JJ
pulmonary	JJ
fibrosis	NN
when	WRB
administered	VBN
either	CC
prophylactically	RB
ortherapeutically	RB
.	.

In	IN
summary	NN
,	,
these	DT
results	NNS
strongly	RB
suggest	VBP
that	IN
inhibition	NN
of	IN
MAP3K19	NN
may	MD
have	VB
a	DT
beneficial	JJ
therapeutic	JJ
effect	NN
in	IN
the	DT
treatment	NN
of	IN
IPF	NN
and	CC
represents	VBZ
a	DT
novel	JJ
strategy	NN
to	TO
target	VB
this	DT
disease	NN
.	.

